Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, ...

A proposed 148-home subdivision on Waynesville's outskirts poses an increasingly familiar quandary: it would provide much needed housing, but forever alter the landscape by developing 56 ...

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates ...

Highlight Therapeutics announces completion of enrollment for Phase 2b study of BO-112 in large, underserved basal cell ...

Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.

DoD-Funded Study Accelerates Novel PTSD Mechanism into Trials; Proven Alcohol Safety Profile De-Risks Program for ...

Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

PLT012 received FDA fast track status for liver cancer, with an ongoing trial evaluating safety and early activity of the CD36-targeting immunotherapy.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

Del-desiran (also known as AOC1001) is an antibody-oligonucleotide conjugate comprised of a DMPK small interfering RNA (siRNA ...

Participants taking the highest dose of the retatrutide drug lost an average of 28.7% of their body weight in a late-stage trial — but for some, it was too effective.